Modular Medical Unveils Plans for Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Yahoo Finance
Public Offering Announcement: Modular Medical, Inc. has initiated an underwritten public offering of its common stock and warrants, aimed at adult users of its FDA-cleared insulin delivery patch pump.
Underwriter Details: Newbridge Securities Corporation is the sole bookrunner for the offering, which includes a potential 30-day option for the underwriter to purchase an additional 15% of the shares.
Regulatory Compliance: The offering is conducted under an effective shelf registration statement with the SEC, and all securities will be sold by Modular Medical.
Company Mission: Modular Medical aims to enhance insulin delivery technology, making it more accessible and user-friendly for individuals with diabetes, moving beyond just "superusers."
Get Free Real-Time Notifications for Any Stock
Monitor tickers like MODD with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on MODD
About MODD
Modular Medical, Inc. is a development-stage medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include two parts - one reusable, one disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; disposable portion removable at any time from an adhesive-backed retainer, which remains in place, and no external controller required, no charging and no battery replacement. MODD1 comes with a variety of methods for the patient to wear the pump. Options include a baseplate with adhesive for attaching to the body that has features for holding the pump to the patient, and overwraps to hold the product to the patient.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Plus Therapeutics Prices Public Offering, Raising $15 Million
- Financing Update: Plus Therapeutics announced the pricing of 39,473,684 units at $0.38 each, expecting to raise approximately $15 million, which will provide fresh capital to advance its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers.
- Market Performance: Connect Biopharma's stock rose 5.96% to $2.31 without any new news, reflecting ongoing investor interest in its lead candidate rademikibart's new mechanism of action data and strategic priorities for 2026.
- Sector Momentum: ABVC BioPharma's shares increased by 3.37% to $2.15, suggesting that investor interest may be driven by broader momentum in the biotech sector despite the absence of new corporate updates.
- Clinical Progress: Traws Pharma's stock rose 2.82% to $1.82 following its announcement of filing a U.S. IND application for tivoxavir marboxil, further supporting investor optimism around the company's pipeline.
Continue Reading
Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%
- Earnings Beat: Tilray Brands reported Q2 earnings of $0.01 per share, surpassing the market expectation of a $0.20 loss, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved quarterly revenue of $217.51 million, exceeding the consensus estimate of $210.95 million, demonstrating success in market demand and sales strategies, which further solidifies its market position.
- Stock Price Surge: Following the positive earnings report, Tilray Brands' shares rose 7.3% to $9.80 in pre-market trading, reflecting investor optimism about the company's future growth potential.
- Positive Market Reaction: The strong performance post-earnings release may attract more investor attention, enhancing the company's appeal in a competitive market landscape.
Continue Reading